{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:39:11Z","timestamp":1760240351458,"version":"build-2065373602"},"reference-count":45,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Medical and Pharmaceutical Sciences of the Transylvanian Museum Society and Semmelweis University","award":["54.4\/2016"],"award-info":[{"award-number":["54.4\/2016"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The use of the dopamine-partial agonist subclass (also termed dopamine stabilizers) of atypical antipsychotics for the treatment of negative schizophrenia symptoms and some mood disorders has increased recently. Similar to other second-generation antipsychotics (SGAs), aripiprazole (ARI) and cariprazine (CAR) also influence food intake, but the peripheral effects of these drugs on adipose\u2013tissue homeostasis, including adipokine secretion as well as lipo- and adipogenesis, are not fully elucidated. In this study, we explored the adipocyte-related mechanisms induced by second-generation antipsychotics (SGAs), leading to changes in peripheral signals involved in energy homeostasis. Materials and Methods: CAR, a new SGA, was compared with ARI and olanzapine (OLA), using cell cultures to study adipogenesis, and the expression levels of peroxisome proliferator-activated receptor-\u03b3 (PPAR-\u03b3) was measured in adipocytes derived from mouse fibroblasts, by western blotting on days 7, 14, and 21 postinduction. The triglyceride (TG) content of the cells was also evaluated on day 15 using Oil Red O staining, and the adiponectin (AN) content in the cell culture supernatants was quantified on days 7 and 15 by enzyme-linked immunosorbent assay. Cells were treated with two concentrations of ARI (0.5 and 20 \u00b5g\/mL), OLA (1 and 20 \u00b5g\/mL), and CAR (0.1 and 2 \u00b5g\/mL). Results: Both concentrations of ARI and OLA, as well as the lower concentration of CAR, significantly increased the TG contents. The AN levels in the supernatants were significantly increased by the higher concentration of ARI on days 7 and 15 (p &lt; 0.05). Although PPAR-\u03b3 levels were not significantly affected by ARI and OLA, the lower concentration of CAR induced a significant time-dependent decrease in PPAR-\u03b3 expression (p &lt; 0.05). Conclusions: The in vitro adipogenesis considered from TG accumulation, AN secretion, and PPAR-\u03b3 expression was differently influenced by ARI, CAR, and OLA. Understanding the adipocyte-related mechanisms of antipsychotics could contribute to understanding their weight-influencing effect.<\/jats:p>","DOI":"10.3390\/medicina55050160","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T11:06:46Z","timestamp":1558091206000},"page":"160","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of Cariprazine, Aripiprazole, and Olanzapine on Mouse Fibroblast Culture: Changes in Adiponectin Contents in Supernatants, Triglyceride Accumulation, and Peroxisome Proliferator-Activated Receptor-\u03b3 Expression"],"prefix":"10.3390","volume":"55","author":[{"given":"L\u00e1szl\u00f3-Istv\u00e1n","family":"B\u00e1ba","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, University of Medicine, Pharmacy, Sciences and Technology of T\u00eergu Mure\u0219, 540139 T\u00eergu Mure\u0219, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0628-035X","authenticated-orcid":false,"given":"Melinda","family":"Kolcs\u00e1r","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, University of Medicine, Pharmacy, Sciences and Technology of T\u00eergu Mure\u0219, 540139 T\u00eergu Mure\u0219, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imre Zolt\u00e1n","family":"Kun","sequence":"additional","affiliation":[{"name":"Doctoral School, Faculty of Medicine, University of Medicine, Pharmacy, Sciences and Technology of T\u00eergu Mure\u0219, 540139 T\u00eergu Mure\u0219, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zs\u00f3fia","family":"Ulakcsai","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics, Semmelweis University, 1089 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fruzsina","family":"Bagam\u00e9ry","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics, Semmelweis University, 1089 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9va","family":"Sz\u00f6k\u0151","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics, Semmelweis University, 1089 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5343-0205","authenticated-orcid":false,"given":"Tam\u00e1s","family":"T\u00e1bi","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics, Semmelweis University, 1089 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9091-277X","authenticated-orcid":false,"given":"Zsolt","family":"G\u00e1ll","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, University of Medicine, Pharmacy, Sciences and Technology of T\u00eergu Mure\u0219, 540139 T\u00eergu Mure\u0219, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,5,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1517\/14656566.7.13.1739","article-title":"A review of atypical antipsychotic drugs versus conventional medication in schizophrenia","volume":"7","author":"Luft","year":"2006","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0306-4530(02)00110-5","article-title":"Efficacy of newer generation antipsychotics in the treatment of schizophrenia","volume":"1","author":"Tandon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coph.2003.09.010","article-title":"What\u2019s atypical about atypical antipsychotic drugs?","volume":"4","author":"Meltzer","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1176\/appi.ajp.159.4.561","article-title":"Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia","volume":"159","author":"Sernyak","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"ref_6","first-page":"617","article-title":"Adverse effects of antipsychotic medications","volume":"81","author":"Muench","year":"2010","journal-title":"Am. Fam. Phys."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0306-4530(02)00114-2","article-title":"A review of the effect of atypical antipsychotics on weight","volume":"28","author":"Nasrallah","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/893629","article-title":"Weight gain, obesity, and psychotropic prescribing","volume":"2011","author":"Nihalani","year":"2011","journal-title":"J. Obes."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1034\/j.1600-0447.2000.101006416.x","article-title":"Atypical antipsychotics and weight gain: A systematic review","volume":"101","author":"Taylor","year":"2000","journal-title":"Acta. Psychiatr. Scand."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1192\/apt.bp.113.011619","article-title":"Metabolic syndrome in psychiatry: Advances in understanding and management","volume":"20","author":"Ho","year":"2014","journal-title":"Adv. Psychiatr. Treat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.pharmthera.2010.04.008","article-title":"Potential mechanisms of atypical antipsychotic-induced metabolic derangement: Clues for understanding obesity and novel drug design","volume":"127","author":"Coccurello","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/pr.117.014381","article-title":"Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery","volume":"70","author":"Atkin","year":"2018","journal-title":"Pharmacol Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2165\/11596300-000000000-00000","article-title":"Atypical antipsychotic-induced weight gain: Insights into mechanisms of action","volume":"25","author":"Roering","year":"2011","journal-title":"CNS Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/ijcp.12752","article-title":"The ABC\u2019s of dopamine receptor partial agonists\u2014Aripiprazole, brexpiprazole and cariprazine: The 15-min challenge to sort these agents out","volume":"69","author":"Citrome","year":"2015","journal-title":"Int. J. Clin. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1210\/jc.2004-0395","article-title":"Adipose tissue as an endocrine organ","volume":"89","author":"Kershaw","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.coph.2006.08.002","article-title":"Role of adipokines in the control of energy metabolism: Focus on adiponectin","volume":"6","author":"Lafontan","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/ajcn\/81.4.780","article-title":"Association between dietary factors and plasma adiponectin concentrations in men","volume":"81","author":"Pischon","year":"2005","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1172\/JCI29126","article-title":"Adiponectin and adiponectin receptors in insulin resistance, diabetes and the metabolic syndrome","volume":"116","author":"Kadowaki","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1073\/pnas.98.4.2005","article-title":"Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice","volume":"98","author":"Fruebis","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/90984","article-title":"The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/90992","article-title":"The adipocyte-secreted protein Acrp30 enhances hepatic insulin action","volume":"7","author":"Berg","year":"2001","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00018-003-3216-3","article-title":"Peroxisome proliferator-activated receptor alpha target genes","volume":"61","author":"Mandard","year":"2004","journal-title":"Cell. Mol. Life. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Moseti, D., Regassa, A., and Kim, W.K. (2016). Molecular regulation of adipogenesis and potential anti-adipogenic bioactive molecules. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17010124"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1074\/jbc.M505311200","article-title":"Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor \u03b3 agonists","volume":"281","author":"Nawrocki","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2007.05.007","article-title":"Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells","volume":"56","author":"Yang","year":"2007","journal-title":"Pharmacol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1038\/tp.2015.161","article-title":"A potential mechanism underlying atypical antipsychotics-induced lipid disturbances","volume":"5","author":"Cai","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41598-017-02884-w","article-title":"Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.1128\/MCB.19.8.5495","article-title":"Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1\/sterol regulatory element binding protein 1: Implications for adipocyte differentiation and metabolism","volume":"19","author":"Fajas","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.bbrc.2014.07.005","article-title":"Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in vitro","volume":"450","author":"Uray","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Nagy, A., Gertsenstein, M., Vintersten, K., and Behringer, R. (2006). Preparing Feeder Cell Layers from STO or Mouse Embryo Fibroblast (MEF) Cells: Treatment with \u03b3-Irradiation. CSH Protoc., 1.","DOI":"10.1101\/pdb.prot4400"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/15622970701361255","article-title":"Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects","volume":"9","author":"Kirschbaum","year":"2008","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Lu, M.L., Wu, Y.X., Chen, C.H., Kuo, P.T., Chen, Y.H., Lin, C.H., and Wu, T.H. (2016). Application of Plasma Levels of Olanzapine and n-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0148539"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/DDDT.S95100","article-title":"Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)","volume":"10","author":"Nakamura","year":"2016","journal-title":"Drug. Des. Devel. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/BF00316069","article-title":"Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O","volume":"97","year":"1992","journal-title":"Histochemistry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/sj.mp.4001948","article-title":"Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment","volume":"12","author":"Even","year":"2007","journal-title":"Mol. Psychiatry"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/17425255.2013.759211","article-title":"Cariprazine: Chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability","volume":"9","author":"Citrome","year":"2013","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3923\/ijp.2013.251.257","article-title":"Adipocyte triglyceride content and adipogenesis in aripiprazole treated rats","volume":"9","author":"Vancea","year":"2013","journal-title":"Int. J. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/sj.npp.1301142","article-title":"Atypical antipsychotic drugs directly impair insulin action in adipocytes: Effects on glucose transport, lipogenesis, and antilipolysis","volume":"32","author":"Vestri","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jcyt.2014.05.005","article-title":"Secreted adiponectin as a marker to evaluate in vitro the adipogenic differentiation of human mesenchymal stromal cells","volume":"16","author":"Martella","year":"2014","journal-title":"Cytotherapy"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2353\/ajpath.2010.090647","article-title":"Enhanced metabolic flexibility associated with elevated adiponectin levels","volume":"176","author":"Asterholm","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2478\/acph-2014-0036","article-title":"Therapeutic drug monitoring of atypical antipsychotic drugs","volume":"64","author":"Grundmann","year":"2014","journal-title":"Acta. Pharm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.metabol.2013.01.025","article-title":"Inhibition of ERK1\/2 pathway suppresses adiponectin secretion via accelerating protein degradation by Ubiquitin-proteasome system: Relevance to obesity-related adiponectin decline","volume":"62","author":"Gu","year":"2013","journal-title":"Metabolism"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Ruiz-Ojeda, J.F., Rup\u00e9rez, A.I., Gomez-Llorente, C., Gil, A., and Aguilera, C.M. (2016). Cell models and their application for studying adipogenic differentiation in relation to obesity: A review. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17071040"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/5\/160\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:53:16Z","timestamp":1760187196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/55\/5\/160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,17]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5]]}},"alternative-id":["medicina55050160"],"URL":"https:\/\/doi.org\/10.3390\/medicina55050160","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2019,5,17]]}}}